Business Context and Reporting Period
Company: Know Labs, Inc. (Note: Request metadata listed "USBC, Inc." but the filing is for Know Labs, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 15, 2024
Event: Entry into a Material Definitive Agreement for a registered direct offering.
Key Financial Metrics
This filing reports a capital raise event rather than periodic operating results. Specific metrics include:
- Aggregate Proceeds: $1,655,000 gross.
- Securities Issued: 6,365,385 Units.
- Unit Composition: One share of Common Stock and one Warrant per Unit.
- Offering Price: $0.26 per Unit.
- Warrant Exercise Price: $0.26 per share.
- Advisory Fees: 5% cash fee of gross proceeds plus issuance of 636,538 Warrants to advisors (Boustead Securities, LLC and The Benchmark Company, LLC).
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of 6,365,385 new shares and associated warrants. The company has also granted advisors a right of first refusal for future public and private equity offerings.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: Management intends to use net proceeds primarily for:
- Product development of the KnowU glucose monitoring products.
- Sales and marketing efforts.
- Clinical studies.
- Intellectual property development.
- Operating expenses and working capital.
Investment Strategy: Pending final application, net proceeds will be invested in short-term, interest-bearing, investment-grade securities.
Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from anticipated results due to risk factors detailed in the company's 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 5% advisory cash fee and other transaction costs.
- Review the full text of the Subscription Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Confirm the dilution impact on existing shareholders given the issuance of 6,365,385 new shares plus 636,538 advisor warrants.
- Check the company's most recent 10-Q or 10-K for current cash balances and working capital needs to assess the sufficiency of the $1.655M raise.
- Monitor the progress of the KnowU glucose monitoring product clinical studies as a key driver for future valuation.